drugset / Trial / NCT02532634
Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
Phase 4
Completed
292 enrolled
Kangdong Sacred Heart Hospital
Astellas Pharma Korea, Inc. · collabThe Catholic University of Korea · collab
RandomizedParallel-groupSingle-blindSupportive care
Summary
The purpose of this study is to compare the anti-emetic effect of ramosetron plus aprepitant and dexamethasone with palonosetron plus aprepitant and dexamethasone in patients receiving highly emetogenic chemotherapy.
Timeline
- Start
- 2015-08-19
- Primary completion
- 2018-05-08
- Completion
- 2018-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |
| Subject | Ramosetron | Small molecule | 0.3 mg | Intravenous |
| Background | Aprepitant | Other / unclassified | 80 mg | Oral |
| Background | Dexamethasone | Small molecule | 8 mg | Intravenous |